

CURRICULUM VITAE

Elizabeth Jane Ivy Read, M.D.

Work Address

Blood Systems Research Institute
270 Masonic Avenue
San Francisco, CA 94118

Office 415-749-6607
Mobile 415-215-4131
Email eread@bloodsystems.org

Education

A.B. (cum laude), 1973
Bryn Mawr College, Bryn Mawr, Pennsylvania

M.D., 1977
SUNY at Buffalo School of Medicine, Buffalo, New York

Honors/Awards

American Medical Women's Association Achievement
Citation for class ranking in top 10%, 1977

Philip P. Sang Memorial Award in Internal Medicine, 1977

NIH Director's Award, 2006

Postgraduate Training and Professional Appointments

- 1977-1980 Intern and Resident in Internal Medicine, George Washington University Medical Center, Washington, D.C.
- 1980-1982 Fellow in Hematology and Oncology, George Washington University Medical Center and Washington Veterans Administration Hospital, Washington, D.C.
- 1982-1984 Cancer Expert, Clinical Investigations Branch, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, Maryland
- 1984-1986 Senior Staff Fellow, Department of Transfusion Medicine, National Institutes of Health, Bethesda, Maryland
- 1986-1988 Medical Officer, Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, Maryland
- 1988-1991 Chief, Special Services Laboratory, Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, Maryland

- 1991-1992 Medical Director, Stem Cell Processing and Cryopreservation Laboratory, and Associate Medical Director, Blood Bank and Transfusion Service, University of Utah Medical Center, Salt Lake City, Utah
- 1992-1995 Medical Director, American Red Cross Blood & Tissue Services, Southern California Region, Los Angeles, California
- 1995-2006 Medical Director and Chief, Cell Processing Section, Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, Maryland
- 2006- Director, Cell and Tissue Therapies, Blood Systems Research Institute, San Francisco, California
- 2007- Adjunct Professor of Laboratory Medicine, University of California, San Francisco

Professional Activities and Committee Appointments (Selected)

- 1988-1991 Chair, Transfusion Committee, NIH Clinical Center
- 1988-1991 Member, Quality Assurance Committee, NIH Clinical Center
- 1990-1991 Member, Radiation Safety Committee, NIH Clinical Center
- 1992-1999 Member, Editorial Board, Journal of Hematotherapy
- 1984- Reviewer, Blood, Journal of Clinical Apheresis, Transfusion
- 1991-1995 Member, Scientific Section Coordinating Committee, American Association of Blood Banks
- 1992-1995 Member, California Blood Bank Society
Transfusion-Transmitted Diseases Committee, 1993-1995
Physician's Committee, 1994-1995
Scientific Program Committee, 1994-1995
- 1992-1995 Member, Medical Advisory Committee, Blood Centers of California
- 1995-1996 Chair, Hematopoietic and Cellular Therapies Committee, American Association of Blood Banks
- 1995-1997 Member, Standards Committee, American Association of Blood Banks
- 1993-1995 Member, Research and Publications Committee, National Marrow Donor Program
- 1995-1999 Member, Data Safety and Monitoring Board, Viral Activation Transfusion Study (VATS), National Heart Lung and Blood Institute

- 1996-1997 Member, Hematopoietic Progenitor Cell Standards Task Force, American Association of Blood Banks
- 1996-1998 Member, Institutional Review Board, American Red Cross Blood Services, Holland Laboratory
- 1998-2000 Member, Ad Hoc Advisory Panel on Gene and Cell Therapies, United States Pharmacopeia
- 1998-2000 Member, Hematopoietic Progenitor Cell Standards Committee, American Association of Blood Banks
- 1998-2005 Reviewer, Advanced Technology Grant Program, National Institute of Standards and Technology, US Department of Commerce
- 1999-2001 Member, Advisory Board, International Society for Hematotherapy and Graft Engineering
- 1999- Member, Editorial Board, Cytotherapy
- 1999 Member, Advisory Committee for Year 2000 Blood Data Survey, National Blood Data Resource Center
- 2000-2004 Member, Selection of Abstracts Committee, American Association of Blood Banks
- 2000-2006 Member, NIH Gene Therapy Data and Safety Assessment Working Group
- 2002-2003 Chair, Somatic Cell Therapy Standards Work Group, American Association of Blood Banks
- 2003-2006 Member, Legal and Regulatory Affairs Committee, International Society for Cellular Therapy
- 2004 Co-Chair, Needs Assessment Task Force, Stem Cell Interest Group, National Institutes of Health
- 2004-2005 Member, Cell Therapy Strategic Planning Work Group, American Association of Blood Banks
- 2004-2006 Member, Inter-Agency Hematopoietic Stem Cell Transplantation Work Group, US Department of Health and Human Services
- 2004-2005 Co-Chair, Release Testing Work Group, International Society for Cell Therapy
- 2005- Member, Biologics and Biotechnology Cell, Tissue and Gene Therapy Expert Committee, United States Pharmacopeia
Chair, Flow Cytometry Panel

Liaison to Plasma & Plasma Products Panel

- 2005- Member, Cellular Therapies Committee, American Association of Blood Banks
- 2006-2007 Member, Data Safety and Monitoring Board, Stem Cell Therapy as Adjunct to Revascularization (STAR) Trial, Veterans Administration Merit Review Study
- 2006- Member, Organizing Committee, Annual Pharma Conference on "FDA and the Changing Paradigm for HCT/P Regulation"
- 2007- Co-Chair, Organizing Committee, Annual Somatic Cell Therapy Symposium (International Society for Cellular Therapy)
- 2007- Member, Advisory Committee for Blood Stem Cell Transplantation, Health Resources and Services Administration, US Department of Health and Human Services

Medical Licensure

District of Columbia (#11965), 1979-present
Utah (#1057610010), 1991-1993
California (#G076603) 1993-1996

Board Certification

Diplomate, American Board of Internal Medicine, 1980
Diplomate, Hematology Subspecialty, ABIM, 1982
Diplomate, Medical Oncology Subspecialty, ABIM, 1983
Diplomate, American Board of Pathology, Special
Qualification in Blood Banking, 1985

Presentations (Selected)

“Implementation of cGMP in a Hospital-Based Laboratory”

Invited lecture at GMP 2000 Workshop, San Francisco, California, November 30, 2000.

“Quantitation of Chimerism Following Hematopoietic Stem Cell Transplantation”

Invited lecture at the 21st meeting of the BEST Working Party of the International Society for Blood Transfusion, Paris, France, May 5, 2001.

“Transplantation of Pancreatic Islets for Treatment of Diabetes Mellitus”

Invited lecture at the Quality Symposium, Adelaide, Australia, October 3-4, 2001.

“Documentation of Personnel Training”

Invited lecture at the Quality Symposium, Adelaide, Australia, October 3-4, 2001.

“T-Cell Depletion of Hematopoietic Progenitor Cell Products for Allogeneic Transplantation”

Invited lecture at the Scientific Symposium, Annual Meeting of the American Association of Blood Banks, San Antonio, Texas, October 17, 2001.

“Isolation of Pancreatic Islets for Transplantation in Type I Diabetes Mellitus”

Invited lecture at the Scientific Symposium, Annual Meeting of the American Association of Blood Banks, San Antonio, Texas, October 17, 2001.

“Personnel Qualifications & Creating a Competency Program”

Invited lecture at GMP 2001 Workshop, Orlando, Florida, December 6, 2001.

“Design and Operation of a Multi-Use Cell Therapy Facility”

Invited lecture at the Second Annual Somatic Cell Therapy Symposium, Sanibel Island, Florida, May 3-5, 2002.

“The New Regulatory Environment for Cellular Therapy Products: Challenges for Academic-Based Manufacturing Facilities”

Invited lecture at the 27th Sanquin International Symposium on Blood Transfusion, Groningen, Netherlands, October 10, 2002.

“The New Regulatory Environment for Cell Therapy Products”

Invited lecture at Annual Seminar, Annual Meeting of the Mid-Atlantic Association of Blood Banks, Williamsburg, Virginia, March 21, 2003.

“Validation of a Commercial Software System at the User Site”

Invited lecture “Computer Validation”, CGTP 2003 Workshop, Annual Meeting of the International Society for Cellular Therapy, Phoenix, Arizona, May 28, 2003.

“Master File of Facility, Operational, and Quality Systems for Manufacture of Cell Therapy Products”

Invited lecture for “Preparation of Clinical INDs”, CGTP 2003 Workshop, Annual Meeting of the International Society for Cellular Therapy, Phoenix, Arizona, May 28, 2003.

“Sterility Testing of Cellular Therapy Products”

Invited presentation at a workshop on Release Testing, Annual Meeting of the International Society for Cellular Therapy, Phoenix, Arizona, May 29-June 1, 2003.

“Cell Therapy and Stem Cell Transplantation”

Invited lecture at NHLBI-sponsored symposium “Allogeneic Stem Cell Transplantation: A Decade of Progress”, NIH, Bethesda, MD, September 11, 2003.

“Innovation Meets Quality: Cellular Therapies in the 21st Century”

Invited lecture at NIH DTM Annual Symposium, Bethesda, MD, October 3, 2003.

“Monocyte Enrichment for Dendritic Cell Immunotherapy Using the Elutra Cell Separation System”

Invited lecture at Annual Meeting of the International Society for Cell Therapy, Dublin, Ireland, May 7-11, 2004.

“Enrichment of Peripheral Blood Monocytes for Dendritic Cell Immunotherapy using the Elutra Cell Separation System”

Oral abstract presentation in “New Technologies” series, Annual Meeting of the International Society for Cell Therapy, Dublin, Ireland, May 7-11, 2004.

“New Directions in Release Testing of Cell Therapy Products: Detection of Microbial Contamination”

Invited panel co-chair presentation at Annual Meeting of the International Society for Cell Therapy, Dublin, Ireland, May 7-11, 2004.

“Moving Stem Cells from the Lab to the Clinic”

Invited lecture for Clinical Stem Cell Interest Group Workshop, NIH, Bethesda, MD, May 24, 2004.

“Preparation of Cell Therapy Products for Cardiovascular Regenerative Medicine”

Invited lecture for Symposium on Cardiovascular Regenerative Medicine, NIH, Bethesda, MD, September 13, 2004.

“Standards and Guidelines for Stem Cell Donors”

Invited panel chair presentation at NHLBI-sponsored Workshop on Safety for Stem Cell Donors, Arlington, Virginia, September 22, 2004.

“Laboratory Drug Master File”

Invited panel chair presentation at Fourth Annual Somatic Cell Therapy Symposium, Houston, Texas, October 1-3, 2004.

“Sterility Testing of Cell Therapy Products”

Invited lecture for workshop on “Release Testing of Cell Therapy Products”, Annual Meeting of the American Association of Blood, Baltimore, MD, October 23, 2004.

“Stem Cell Processing and Graft Engineering”

Invited lecture at symposium on “Cell Therapies for Autoimmune Disease”, NIAMS, NIH, Bethesda, MD, November 10, 2004.

“Adverse Event and Deviation Reporting”

Invited workshop co-leader presentation at Pharma Conference on “FDA and the New Paradigm for Tissue Regulation”, Dallas, Texas, February 1-3, 2005.

“Reporting Adverse Events and Deviations for Cell Therapy Products”

Invited panel chair presentation at CGTP 2005 Workshop, Annual Meeting of the International Society for Cellular Therapy, Vancouver, BC, Canada, May 4, 2005 (Panel organized and materials prepared by EJR; lecture presented by Dr. Hanh Khuu).

“Reporting Adverse Events & Deviations”

Invited panel chair presentation at Fifth Annual Somatic Cell Therapy Symposium, Bethesda, MD, September 18, 2005.

“Clinical Cell Therapies: Challenges and Promise”

Invited lecture at Blood Systems Research Institute, San Francisco, California, September 22, 2005.

“Reporting Adverse Events and Deviations for Cell Therapy Products”

Invited workshop chair presentation at Pharma Conference “FDA and the Changing Paradigm for Tissue Regulation”, Las Vegas, NV, February 9, 2006.

“Innovation Meets Quality: The Challenges and Promise of Clinical Cell Therapies”

Invited lecture for Laboratory Medicine Grand Rounds, UCSF Medical Center, San Francisco, California, March 20, 2006.

“Manufacturing Issues for G-CSF Mobilized Hematopoietic Progenitor Cells Transduced with Retroviral Vectors”

Invited presentation at American Society of Gene Therapy annual meeting, Baltimore, MD, May 31, 2006.

“Receipt, Thaw, and Infusion of Cord Blood”

Invited presentation at meeting of US Department of Health & Human Services Inter-Agency Hematopoietic Stem Cell Consortium, Bethesda, MD, June 6, 2006.

“Overview of FDA Regulations for Reporting Adverse Events and Deviations for Cell Therapy Products”

Invited presentation for AABB Audioconference, June 7, 2006.

“Microbial Testing of Cell Therapy Products”

Invited presentation for FDA Cell Therapy Liaison group, Bethesda, MD, June 16, 2006.

“Adverse Event & Deviation Reporting for 351 Cell Therapy Products”

Invited panel chair presentation at Sixth Annual Somatic Cell Therapy Symposium, Bethesda, MD, September 25, 2006.

“Recent Experience with Cell Therapy INDs at the NIH Clinical Center”

Invited workshop panel presentation at Sixth Annual Somatic Cell Therapy Symposium, Bethesda, MD, September 26, 2006.

“Cord Blood from Matched Unrelated Donors: Receipt, Thaw, and Infusion”
Invited presentation for the NIH Stem Cell Transplantation Interest Group, Bethesda, MD, October 18, 2006.

“Use of Closed Automated Systems in Cell Therapy Product Manufacturing” and
“Evaluation of Closed Systems in Dendritic Cell Manufacturing”
Invited workshop presentations at AABB Annual Meeting, Miami, FL, October 22, 2006.

“Cord Blood from Matched Unrelated Donors: Receipt, Thaw, and Infusion”
Invited workshop presentation for “Setting the Stage for Successful Cord Blood Unit Receipt, Thaw, and Infusion” at NMDP Council Meeting, Minneapolis, MN, November 11, 2006.

“Management of Cell Therapy Products with Positive Microbial Cultures”
Invited workshop co-chair presentation at Pharma Conference “FDA and the Changing Paradigm for HCT/P Regulation”, San Antonio, TX, January 24, 2007.

“Proposal for Public Cord Blood Banking in Arizona”
Presentation to the Arizona State Senate Health Committee, Phoenix, AZ, February 1, 2007.

“Development of Dendritic Cell Cancer Vaccines for Early Phase Clinical Trials in an Academic Facility”
Invited panel presentation at NCI/FDA Workshop “Bringing Therapeutic Cancer Vaccines and Immunotherapies through Development to Licensure”, Bethesda, MD, February 8, 2007.

“Comments of the International Society (ISCT) for Cellular Therapy to FDA Cellular, Tissue, and Gene Therapies Advisory Committee on Cord Blood Draft Guidance”
Presentation during public comments session at FDA Advisory Committee meeting, March 30, 2007.

“Bench to Bedside Translation of Cell & Tissue Therapies”
Presentation at Blood Systems/UBS Medical Directors’ Annual Meeting, San Francisco, CA, May 11-12, 2007.

“Introduction to Cell & Tissue Therapies”
Lecture for UCSF Biomedical Sciences graduate school Stem Cell course, San Francisco, CA, May 22, 2007.

“Unlicensed Cord Blood Products: What Should We Do?” Invited presentation at FDA/CBER OCGT Cell Therapy Liaison Meeting, Bethesda, MD, June 7, 2007.

“Stability Testing of Cell Therapy Products”
AABB Audioconference on Storage and Stability Programs for Cell Therapy Products, June 27, 2007

“Bench to Bedside Translation of Cell & Tissue Therapies”
ABC Annual Meeting, Vancouver, BC, Canada, August 4, 2007.

“Bench to Bedside Translation of Cell & Tissue Therapies”
IABS meeting, Sao Paulo, Brazil, September 19, 2007.

Meeting Chair, and Chair for session on Product Sterility Testing
Somatic Cell Therapy Symposium, Bethesda, MD, September 26-28, 2007

“Management of Cell Therapy Products from Ineligible Donors”
AABB Audioconference on HCT/P Donor Dilemmas, October 3, 2007

“CGMPs, CGTPs, and Regulations for Cell & Tissue Therapies”
Blood Systems Audioconference, October 10, 2007.

Workshop Chair, “Application of New Technologies to Cell and Tissue Processing”
AABB Annual Meeting, Anaheim, CA, October 20, 2007.

“Donor Eligibility Issues for Cell Therapy Products”
Invited workshop co-chair presentation at Pharma Conference “FDA and the Changing
Paradigm for HCT/P Regulation”, San Antonio, TX, January 9, 2008.

Original Papers, Book Chapters, and Edited Publications

1. **Read EJ**, Orenstein JM, Chorba TL, Schwartz AM, Simon GL, Lewis JH, Schulof RS. Listeria monocytogenes sepsis and small cell carcinoma of the rectum: an unusual presentation of the acquired immunodeficiency syndrome. Am J Clin Pathol 1985;83:385-89.
2. Looney WB, Goldie JH, Little JB, **Read EJ**, Wittes R. Alternation of chemotherapy and radiotherapy in cancer management. I. Summary of the Division of Cancer Treatment Workshop. Cancer Treatment Reports 1985;69:769-75.
3. **Read EJ**, Klein HG. Hematologic effects of aging: Considerations for clinical trials. In Cutler NR and Narang PK (eds): Drug Studies in the Elderly: Methodological Concerns. New York: Plenum, 1986:123-50.
4. **Read EJ**, Carter CS. Radiolabeled platelet survival studies (letter). Transfusion 1986;26:490-1.
5. **Read EJ**. Leukocyte Radiolabeling. In Davey RJ and Wallace MH (eds): Diagnostic and Investigational Uses of Radiolabeled Blood Elements. Arlington, VA: American Association of Blood Banks, 1987:93-114.
6. Areman EM, Simonis T, Carter CS, **Read EJ**, Klein HG. Bulk cryopreservation of lymphocytes in glycerol. Transfusion 1988;28:151-56.
7. **Read EJ**, Kodis C, Carter CS, Leitman SF. Viability of platelets following storage in the irradiated state: A pair-controlled study. Transfusion 1988;28:446-50.
8. Fisher B, Packard BS, **Read EJ**, Carasquillo JA, Carter CS, Topalian SL, Yang JC, Yolles P, Larson SM, Rosenberg SA. Tumor localization of adoptively transferred indium-111 labeled tumor infiltrating lymphocytes in patients with metastatic melanoma. J Clin Oncol 1989;7:250-61.
9. Leitman SF, Klein HG, Melpolder JJ, **Read EJ**, Esteban JI, Leonard EM, Harvath L, Shih JWK, Nealon R, Darr F, Alter HJ. Clinical implications of positive tests for antibodies to human immunodeficiency virus type 1 in asymptomatic blood donors. New Engl J Med 1989;321:917-24.
10. Griffith K, **Read EJ**, Carasquillo JA, Carter CS, Yang JC, Fisher B, Aebersold P, Packard BS, Yu MY, Rosenberg SA. In vivo distribution of adoptively transferred indium-111 labeled tumor infiltrating lymphocytes and peripheral blood lymphocytes in patients with metastatic melanoma. J Nat Cancer Inst 1989;81:1709-17.
11. **Read EJ**, Keenan AM, Carter CS, Yolles P, Davey RJ. In vivo traffic of ¹¹¹indium-oxine labeled human lymphocytes collected by automated apheresis. J Nuclear Med 1990;31:999-1006.
12. Abrahamsen TG, Carter CS, **Read EJ**, Rubin M, Goetzman HG, Lizzio EF, Lee YL, Hanson M, Pizzo PA, Hoffman T. Stimulatory effect of counterflow centrifugal

elutriation in large scale separation of peripheral blood monocytes can be reversed by storing the cells at 37C. J Clin Apheresis 1991;6:48-53.

13. **Read EJ**, Cardine L, Yu MY. Flow cytometric determination of human erythrocytes labeled with a fluorescent membrane label: Potential application to in vivo survival studies. Transfusion 1991;31:502-8.
14. **Read EJ**, Carter CS, Cullis HM. Bone marrow cell counting: Methodological issues. In: Gee AP (Ed): Bone marrow processing and purging: A practical guide. CRC Press, Boca Raton: 1991.
15. Parker RI, Barton NW, **Read EJ**, Brady RO. Hematologic improvement in a patient with Gaucher's disease on long-term enzyme replacement therapy: Evidence for decreased splenic sequestration and improved red blood cell survival. Am J Hematol 1991;38:130-137.
16. **Read EJ**, Carter CS. Automated and manual cell counting of bone marrow suspensions. In: Sacher RA, Areman EA, Deeg HJ, (Eds): Bone marrow and stem cell processing: A manual of current techniques. Philadelphia: F.A. Davis, 1992.
17. **Read EJ**, O'Shaughnessy JA, Yu MY, Cottler-Fox M, Denikoff AM, Cowan KH, Gress RE. Flow cytometric quantitation of circulating hematopoietic progenitor cells in breast cancer patients on chemotherapy and GM-CSF. In: Gee AP, Gross S, Worthington-White DA (Eds): Bone marrow purging and processing. New York: Wiley-Liss, Progress in Clinical and Biological Research, 1992;377:523-30.
18. Cottler-Fox M, **Read EJ**, Yu MY, Carter CS, Klein HG. Mononuclear and CD34+ stem cell recovery after automated ficoll processing of marrow or peripheral stem cells for transplant. In: Gee AP, Gross S, Worthington-White DA (Eds): Bone marrow purging and processing. New York: Wiley-Liss, Progress in Clinical and Biological Research, 1992;377:569-73.
19. **Read EJ**, Carter CS. Enumeration of cells in bone marrow and peripheral blood stem cell suspensions: Technical issues and prospects for standardization. J Hematotherapy 1992;1:175-82.
20. Chen CC, Kerr GS, Carter CS, **Read EJ**, Carasquillo JA, Leitman SF, Hoffman GS. Lack of sensitivity of Indium-111 mixed leukocyte scans for active disease in Takayasu's arteritis. J Rheumatol 1995;22:478-81.
21. **Read EJ**, Klein HG, eds. Standards for bone marrow and peripheral blood progenitor cells (excerpted from Standards for blood banks and transfusion services, 16th edition). Bethesda, MD: American Association of Blood Banks, 1995.
21. **Read EJ**. Quality assurance for cell processing: No more blind faith (Editorial) Transfusion 1996;36:1-4.
22. Mavroudis D, **Read EJ**, Cottler-Fox M, Couriel D, Mollidrem J, Carter CS, Yu M, Dunbar C, Barrett AJ. CD34+ cell dose predicts survival, post transplant morbidity and rate of hematologic recovery following allogeneic marrow transplants for hematologic malignancies. Blood 1996;88:3223-9.

23. Leitman SF, **Read EJ**. Hematopoietic progenitor cells. Seminars in Hematology 1996;33:341-58.
24. **Read EJ**, Kunitake ST, Carter CS, Chau Q, Yu MY, Klein HG. Enumeration of CD34+ hematopoietic progenitor cells in peripheral blood and leukapheresis products by volumetric capillary cytometry: A comparison with flow cytometry. J Hematotherapy 1997;6:291-301.
25. Leiby DA, **Read EJ**, Lenes BA, Yund J, Stumpf RJ, Kirchoff LV, Dodd RA. Seroepidemiology of *Trypanosoma cruzi*, etiologic agent of Chagas' disease, in U.S. blood donors. J Infect Dis 1997;176:1047-52.
26. Malech HL, Maples PB, Whiting-Theobald, Linton GF, Seksaria S, Vowells SJ, Li F, Miller JA, DeCarlo E, Holland SM, Leitman SF, Carter CS, Butz RE, **Read EJ**, Fleisher TA, Schneiderman RD, VanEpps DE, Spratt SK, Maack CA, Rokovisch JA, Cohen LK, Gallin JI. Production of oxidase corrected granulocytes in vivo following gene therapy of chronic chronic granulomatous disease. Proc Natl Acad Sci USA 1997;94:12133-8.
27. Barrett AJ, Mavroudis D, Molldrem J, Clave E, Dunbar C, Cottler-Fox M, Phang S, Carter C, O'Kunief P, Tisdale J, Young NS, **Read EJ**. T cell-depleted bone marrow transplantation and delayed T cell add-back to control acute GVHD and conserve a graft-versus-leukemia effect. Bone Marrow Transplant 1998;21:543-51.
28. Mavroudis DA, **Read EJ**, Molldrem J, Raptis A, Plante M, Carter CS, Phang S, Dunbar CE, Barrett AJ. T cell depleted granulocyte colony-stimulating factor (G-CSF) modified allogeneic bone marrow transplantation for hematological malignancy improves graft CD34+ cell content but is associated with delayed pancytopenia. Bone Marrow Transplant 1998;21:431-40.
29. Childs R, Clave E, Contentin N, Jayasekera D, Hensel N, Leitman S, **Read EJ**, Carter C, Bahceci E, Barrett AJ. Engraftment kinetics following non-myeloablative allogeneic peripheral blood stem cell transplantation: Full donor T cell chimerism precedes alloimmune responses. Blood 1999;94:3234-41.
30. Liu JM, Kim S, **Read EJ**, Dokal I, Carter CS, Leitman SF, Pensiero M, Young NS, Walsh CE. Engraftment of hematopoietic progenitor cells transduced with the Fanconi anemia group C gene (FANCC). Human Gene Therapy 1999;10:2337-46.
31. Van Rhee F, Jiang Y, Vigue F, Kirby M, Mavroudis D, Hensel N, Agarwala V, Clave E, Childs R, Raptis A, Sloand E, Carter C, **Read EJ**, Barrett J. Human G-CSF-mobilized CD34-positive peripheral blood progenitor cells can stimulate allogeneic T-cell responses: implications for graft rejection in mismatched transplantation. Br J Haematology 1999;105:1014-24.
32. Williams JF, Petrus MJ, Wright JA, Husebekk A, Fellowes V, **Read EJ**, Gress RE, Fowler DH. Fas-mediated lysis of chronic lymphocytic leukaemia cells: Role of type I versus type II cytokines and autologous FasL-expressing T cells. Br J Haematol 1999;107:99-105.

33. Cowan KH, Moscow JA, Huang H, Zujewski J, O'Shaughnessy J, Sorrentino B, Carter C, Schneider E, Cusack G, Noone M, Dunbar C, Steinberg S, Wilson W, Goldspiel B, **Read EJ**, Leitman S, McDonagh K, Chow C, Abati A, Chiang Y, Weir S, Gottesman M, Pastan I, Nienhuis A. Paclitaxel chemotherapy following autologous stem cell transplantation and engraftment of hematopoietic cells transduced with a retrovirus containing the multidrug resistance cDNA (MDR1) in metastatic breast cancer patients. Clinical Cancer Research 1999;5:1619-28.
34. Moscow JA, Huang H, Carter C, Hines K, Zujewski J, Cusack G, Chow C, Venzon D, Sorrentino B, Chiang Y, Goldspiel B, Leitman S, **Read EJ**, Abati A, Gottesman MM, Pastan I, Sellers S, Dunbar C, Cowan K. Engraftment of MDR1 and NeoR gene-transduced hematopoietic cells after breast cancer chemotherapy. Blood 1999; 94:52-61.
35. Bahceci E, **Read EJ**, Leitman SF, Childs R, Dunbar C, Young NS, Barrett AJ. CD34+ cell dose predicts relapse and survival after T-cell-depleted HLA-identical haematopoietic stem cell transplantation for haematological malignancies. Br J Haematol 2000;108:408-14
36. **Read EJ**. Collection of hematopoietic progenitor cells. In: Snyder ES, Haley NR, Eds. Hematopoietic progenitor cells: A primer for medical professionals. Bethesda, MD: AABB Press, 2000; pp 31-54.
37. Husebekk A, Fellowes V, **Read EJ**, Williams J, Petrus MJ, Gress RE, Fowler DH. Selection and expansion of T cells from untreated patients with CLL: source of cells for immune reconstitution? Cytotherapy 2000;2:187-93.
38. Mackall CL, Stein D, Fleisher TA, Brown MR, Hakim FT, Leitman SF, **Read EJ**, Carter CS, Wexler LH, Gress RE. Prolonged CD4 depletion after sequential autologous peripheral blood progenitor cell infusions in children and young adults. Blood 2000;96:754-62.
39. Childs R, Chernoff A, Contentin N, Bahceci E, Schrupp D, Leitman S, **Read EJ**, Tisdale J, Dunbar C, Linehan WM, Young NS, Barrett AJ. Regression of metastatic renal cell carcinoma following nonmyeloablative allogeneic peripheral blood stem cell transplantation. New Engl J Med 2000;343:750-8.
40. Wong ECC, Maher VE, Hines K, Lee J, Carter CS, Goletz T, Kopp W, Mackall CL, Berzofsky JA, **Read EJ**. Generation of dendritic cells from peripheral blood monocytes for use in cancer immunotherapy. Cytotherapy 2001;3:19-30.
41. Horwitz ME, Barrett AJ, Holland SM, Childs R, Miller JA, Leitman SF, **Read EJ**, Carter CS, Brown MR, Linton GF, Gallin JI, Malech HL. Treatment of chronic granulomatous disease with nonmyeloablative marrow conditioning and a T cell-depleted hematopoietic allograft. New Engl J Med 2001;344:881-8.
42. Nakamura R, Bahceci E, **Read EJ**, Leitman SF, Carter CS, Childs R, Dunbar CE, Gress R, Altemis R, Young NS, Barrett AJ. Transplant dose of CD34+ and CD3+ cell predicts outcome in patients with haematological malignancies undergoing T-cell depleted peripheral blood stem cell transplants with delayed donor lymphocyte add-back. Br J Haematol 2001;115:95-104.

43. **Read EJ**. Development of hematopoietic stem cell standards. Transfusion and Apheresis Science 2001;24:185-6.
44. Wong ECC, Lee SM, Hines K, Lee J, Carter SC, Kopp W, Bender J, **Read EJ**. Development of a closed system process for clinical-scale generation of dendritic cells: Evaluation of two monocyte enrichment methods and two culture containers. Cytotherapy 2002;4:65-76.
45. Kang EM, Areman EM, David-Ocampo V, Fitzhugh C, Link ME, **Read EJ**, Leitman SF, Rodgers GP, Tisdale JF. Safety and feasibility of mobilization, collection, and processing of peripheral blood stem cells in individuals with sickle cell trait. Blood 2002;99:850-5.
46. Dagher R, Long LM, **Read EJ**, Leitman SF, Carter CS, Tsokos M, Kumar S, Goletz TJ, Brown MR, Fleisher TA, Bernstein D, Berzofsky JA, Helman LJ, Mackall CL. Pilot trial of tumor-specific peptide vaccination and continuous infusion interleukin-2 in patients with recurrent Ewing sarcoma and alveolar rhabdomyosarcoma: An inter-institute NIH study. Med Pediatr Oncol 2002;38:158-64.
47. Leiby DA, Herron RM, **Read EJ**, Lenes BA, Stumpf RJ. *Trypanosoma cruzi* in Los Angeles and Miami blood donors: Impact of evolving donor demographics on seroprevalence and implications for transfusion transmission. Transfusion 2002;42:549-55.
48. **Read EJ**, Lee J, Harlan DM. Isolation of pancreatic islets for transplantation in type 1 diabetes mellitus. In Sacher R (ed): Cellular Therapy: New Frontiers in Transfusion Medicine. Bethesda, MD: AABB Press, 2002:45-72.
49. **Read EJ**, Carter CS. T-cell depletion of hematopoietic progenitor cell products for allogeneic transplantation. In Sacher R (ed): Cellular Therapy: New Frontiers in Transfusion Medicine. Bethesda, MD: AABB Press, 2002:29-42.
50. Solomon SR, Tran T, Carter CS, Donnelly S, Hensel N, Schindler J, Bahceci E, Ghetie V, Michalek J, Mavroudis D, **Read EJ**, Vitetta ES, Barrett AJ. Optimized clinical-scale culture conditions for ex vivo selective depletion of host-reactive donor lymphocytes: a strategy for GvHD prophylaxis in allogeneic PBSC transplantation. Cytotherapy 2002;4:395-406.
51. Khuu HM, Cowley H, David-Ocampo V, Carter CS, Kasten-Sports C, Wayne AS, Solomon SR, Bishop MR, Childs RM, **Read EJ**. Catastrophic failures of freezing bags for cellular therapy products: Description, cause, and consequences. Cytotherapy 2002;4:539-49.
52. Huhn RD, Fogarty PF, Nakamura R, **Read EJ**, Leitman SF, Rick ME, Greene A, Hansmann K, Gratwohl A, Young N, Barrett AJ, Dunbar CE. High-dose cyclophosphamide with autologous lymphocyte-depleted peripheral blood stem cell (PBSC) support for treatment of refractory chronic autoimmune thrombocytopenia. Blood 2003;101:71-7.
53. Bolan CD, Carter CS, Wesley RA, Yau YY, Barrett AJ, Childs RW, **Read EJ**, Leitman SF. Prospective evaluation of cell kinetics, yields, and donor experiences during a

single large-volume apheresis versus two smaller volume consecutive day collections of allogeneic peripheral blood stem cells. Br J Haematol 2003;120:801-7.

54. Solomon SR, Nakamura R, **Read EJ**, Leitman SF, Carter CS, Childs R, Dunbar CE, Young NS, Barrett AJ. Cyclosporine is required to prevent severe acute GVHD following T-cell-depleted peripheral blood stem cell transplantation. Bone Marrow Transplant 2003; 31:783-8.
55. **Read EJ**. Going where the action is: Cellular therapy for diabetes mellitus. Cytotherapy 2003;5:241-242.
56. **Read EJ**. The new regulatory environment for cellular therapy products: challenges for academic-based manufacturing facilities. In Smit Sibinga CTh and de Ley (eds): Cellular Engineering and Cellular Therapies. Dordrecht: Kluwer Academic Publishers, 2003; pp 45-54.
57. Pomper GJ, Rick ME, Epstein JS, **Read EJ**, Leitman SF. Management of severe VWD with cryoprecipitate collected by repeated apheresis of a single dedicated donor. Transfusion 2003;43:1514-21.
58. Fogarty PF, Yamaguchi H, Wiestner A, Baerlocher GM, Sloand E, Zeng WS, **Read EJ**, Lansdorp PM, Young NS. Late presentation of dyskeratosis congenita as apparently acquired aplastic anemia due to mutations in telomerase RNA. Lancet 2003;362:1628-30.
59. Hirshberg B, Rother KI, Digon BJ, Lee J, Gaglia JL, Hines K, **Read EJ**, Chang R, Wood BJ, Harlan DM. Benefits and risks of solitary islet transplantation for type 1 diabetes mellitus using steroid sparing immunosuppression: the National Institutes of Health experience. Diabetes Care 2003;26:3288-95.
60. **Read EJ**, Sullivan MT. Cellular therapy services provided by blood centers and hospitals in the United States, 1999: an analysis from the Nationwide Blood Collection and Utilization Survey. Transfusion 2004;44:539-46.
61. Arbab AS, Yocum GT, Kalish H, Jordan EK, Anderson SA, Khakoo AY, **Read EJ**, Frank JA. Efficient magnetic cell labeling with protamine sulfate complexed to ferumoxides for cellular MRI. Blood 2004;104(4):1217-23.
62. Khuu HM, Stock F, McGann M, Carter CS, Atkins JW, Murray PR, **Read EJ**. Comparison of automated culture systems with a CFR/USP-compliant method for sterility testing of cell therapy products. Cytotherapy 2004;6:183-95.
63. Stroncek D, **Read EJ**. Cell processing: current status and future directions. Yonsei Med J 2004;45 Suppl:1-4.
64. Bishop MR, Fowler DH, Marchigiani D, Castro K, Kasten-Sportes C, Steinberg SM, Gea-Banacloche JC, Dean R, Chow CK, Carter C, **Read EJ**, Leitman S, Gress R. Allogeneic lymphocytes induce tumor regression of advanced metastatic breast cancer. J Clin Oncol 2004;22:3886-92.

65. Bishop MR, Steinberg SM, Gress RE, Hardy NM, Marchigiani D, Kasten-Sportes C, Dean R, Pavletic SZ, Gea-Banacloche J, Castro K, Hakim F, Krumlauf M, **Read EJ**, Carter C, Leitman SF, Fowler DH. Targeted pretransplant host lymphocyte depletion prior to T-cell depleted reduced-intensity allogeneic stem cell transplantation. Br J Haematol 2004;26:837-43.
66. **Read EJ**. Innovation meets quality: moving cellular therapies at the National Institutes of Health from bench to bedside. Cytotherapy 2004;6:626-8.
67. Powell TM, Paul JD, Hill JM, Thompson M, Benjamin M, Rodrigo M, McCoy JP, **Read EJ**, Khuu HM, Leitman SF, Finkel T, Cannon RO. Granulocyte colony-stimulating factor mobilizes functional endothelial progenitor cells in patients with coronary artery disease. Arterioscler Thromb Vasc Biol 2005;25:296-301.
68. Solomon SR, Mielke S, Savani BN, Montero A, Wisch L, Childs R, Hensel N, Schindler J, Ghetie V, Leitman SF, Mai T, Carter CS, Kurlander R, **Read EJ**, Vitetta ES, Barrett AJ. Selective depletion of alloreactive donor lymphocytes: a novel method to reduce the severity of graft-versus-host disease in older patients undergoing matched sibling donor stem cell transplantation. Blood 2005;106:1123-9
69. Carbone DP, Ciernik F, Kelley MJ, Smith MC, Nadaf S, Kavanaugh DK, Maher VE, Stipanov M, Contois M, Johnson BE, Pendleton CD, Seifert B, Carter C, **Read EJ**, Greenblatt J, Top LE, Kelsey MI, Minna JD, Berzofsky JA. Immunization with mutant p53-and K-ras-derived peptides in cancer patients: immune responses and clinical outcome. J Clin Oncol 2005;23:5099-107.
70. Solomon SR, Savani BN, Childs R, Montero A, Boss C, **Read EJ**, Leitman SF, Barrett AJ. Improved outcome for peripheral blood stem cell transplantation for advanced primary myelodysplastic syndrome. Biol Blood Marrow Transplant 2005;11:619-26.
71. Montero A, Savani BN, Kurlander R, **Read EJ**, Leitman SF, Childs R, Solomon SR, Barrett AJ. Lineage-specific engraftment and outcomes after T-cell-depleted peripheral blood stem cell transplant with Flu/Cy/TBI conditioning. Br J Haematol 2005;130:733-9.
72. Morgan RA, Walker R, Carter CS, Natarajan V, Tavel JA, Bechtel C, Herpin B, Muul L, Zheng Z, Jagannatha S, Bunnell BA, Fellowes V, Metcalf JA, Stevens R, Baseler M, Leitman SF, **Read EJ**, Blaese RM, Lane HC. Preferential survival of CD4+ T lymphocytes engineering with anti-human immunodeficiency virus (HIV) genes in HIV-infected individuals. Hum Gene Ther 2005;16:1065-74.
73. Arbab AS, Yocum GT, Rad AM, Khakoo AY, Fellowes V, **Read EJ**, Frank JA. Labeling of cells with ferumoxides-protamine sulfate complexes does not inhibit function or differentiation capacity of hematopoietic or mesenchymal stem cells. NMR Biomed 2005;18:553-9.
74. Zhang H, Chua K, Guimond M, Kapoor V, Brown M, Fleischer T, Long L, Bernstein D, Douek D, Berzofsky J, Carter CS, **Read EJ**, Helman L, Mackall CL. Lymphopenia and IL2 therapy alter homeostasis of CD4+CD25+ regulatory T cells. Nat Med 2005;11:1238-1243.

75. Hill JM, Syed MA, Arai AE, Powell TM, Paul JD, Zalos G, **Read EJ**, Khuu HM, Leitman SF, Horne M, Csako G, Dunbar CE, Waclawiw MA, Cannon RO 3rd. Outcomes and risks of granulocyte colony-stimulating factor in patients with coronary artery disease. J Am Coll Cardiol 2005;46:1643-8.
76. Arbab AS, Yocum GT, Rad AM, Khakoo AY, Fellow V, **Read EJ**, Frank JA. MRI and confocal microscopy studies of magnetically labeled endothelial progenitor cells trafficking to sites of tumor angiogenesis. Stem Cells 2006;24:671-8.
77. Savani BN, Rezvani K, Mielke S, Montero A, Kurlander R, Carter CS, Leitman S, **Read EJ**, Childs R, Barrett AJ. Factors associated with early molecular remission following T cell depleted allogeneic stem cell transplantation for chronic myelogenous leukemia. Blood 2006;107:1688-95.
78. Moroff G, Eichler H, Brand A, Kekomaki R, Kurtz J, Letowska M, Pamphilon D, **Read EJ**, Porretti L, Lecchi L, Reems J, Sacher R, Seetharaman S, Takahashi TA. Multiple-laboratory comparison of in vitro assays utilized to characterize hematopoietic cells in cord blood. Transfusion 2006;46:507-515.
79. Fowler DH, Odom J, Castro K, Steinberg SM, Chow CK, Foley J, Kogan Y, Hou J, Wayne A, Gea-Banacloche J, Kasten-Sportes C, Dean R, Wilson WH, Pavletic S, Hakim F, Kolstad A, Leitman S, **Read EJ**, Fellowes V, Carter CS, Mair R, Beatty GL, Vonderheide RH, Vance BA, Levine BL, June CH, Gress RE, Bishop MR. Pilot clinical trial of co-stimulated donor Th2-like cells after T cell replete allogeneic hematopoietic stem cell transplantation. Biol Blood Transplant Med 2006;12:1150-60.
80. Montero A, Savani BN, Shenoy A, **Read EJ**, Carter CS, Leitman SF, Mielke S, Rezvani K, Childs R, Barrett AJ. T-cell depleted peripheral blood stem cell allotransplantation with T cell addback for patients with hematological malignancies: effect of chronic GVHD on outcome. Biol Blood Marrow Transplant 2006;12:1318-25.
81. **Read EJ**. Chance favors the prepared mind: A tribute to Charles S Carter Jr (1954-2006). Cytotherapy 2006;8:191-3.
82. Kurlander RJ, Tawab A, Fan Y, Carter CS, **Read EJ**. A functional comparison of mature human dendritic cells prepared in fluorinated ethylene-propylene bags or polystyrene flasks. Transfusion 2006;46:1494-504.
83. Khuu HM, Patel N, Carter CS, Murray PR, **Read EJ**. Sterility testing of cell therapy products: Parallel comparison of automated methods with a CFR-compliant method. Transfusion 2006;46:2071-2082.
84. Sullivan MT, Cotton R, **Read EJ**, Wallace EL. Blood collection and transfusion in the United States in 2001. Transfusion 2006;47:385-94.
85. Mielke S, Rezvani K, Savani BN, Nunes R, Yong AS, Schindler J, Kurlander R, Ghetie V, **Read EJ**, Solomon SR, Vitetta ES, Barrett AJ. Reconstitution of foxp3+ regulatory T cells (Tregs) after CD25-depleted allotransplantation in elderly patients

and association with acute graft-versus-host disease (GcHD). Blood 2007;110:1689-97.

86. Sloand EM, **Read EJ**, Scheinberg P, Tang Y, More K, Leitman SF, Maciejewski J, Young NS. Mobilization, collection, and immunomagnetic selection of peripheral blood CD34 cells in recovered aplastic anemia patients. Transfusion 2007;47:1250-3.
87. Mielke S, Nunes R, Rezvani K, Fellowes VS, Venne A, Solomon SR, Fan Y, Gostick E, Proce DA, Scotto C, **Read EJ**, Barrett AJ. A clinical scale selective allodepletion approach for treatment of HLA-mismatched and matched donor-recipient pairs using expanded T lymphocytes as antigen-presenting cells and a TH9402-based photodepletion technique. Blood 2008;111:4392-402.
88. Eichler H, Nguyen XD, Roelen D, Celluzzi CM, McKenna D, Pamphilon D, Blair A, **Read EJ**, Takahashi TA, Szczepiorkowski ZM, and the BEST Collaborative. Multi-center study on in vitro characterization of dendritic cells. Cytotherapy 2008;10:21-9.
89. Shin JW, Jin P, Fan Y, Slezak S, David-Ocampo V, Khuu HM, **Read EJ**, Wang E, Marincola FM, Stroncek DF. Evaluation of gene expression profiles of immature dendritic cells prepared from peripheral blood mononuclear cells. Transfusion 2008;48:647-57.
90. Mackall CL, Rhee EH, Carter CS, **Read EJ**, Khuu HM, Leitman SF, Bernstein D, Tess M, Long LM, Grindler D, Merino M, Kopp W, Berzofsky, Helman LJ. A pilot study of consolidative immunotherapy in patients with high risk pediatric sarcomas. Clinical Cancer Research 2008, in press.
91. Tawab A, Fan Y, **Read EJ**, Kurlander RJ. Effect of ex vivo culture duration on phenotype and cytokine production by mature dendritic cells derived from peripheral blood monocytes. Transfusion 2008, in press.